A clinical study for Rituximab in the treatment of biliary atresia

Immune pathogenesis and treatment of biliary atresia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031738

Enrollment

Unknown

Registered

2020-04-08

Start date

2020-02-18

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary atresia

Interventions

Control:Conventional therapy

Experimental group:Rituximab

Eligibility

Sex/Gender

All

Age

0.1 Years to 0.3 Years

Inclusion criteria

Inclusion criteria: The participants will be recruited from patients diagnosed of highly suspected BA by experienced senior doctors. Inclusion criteria for this pilot clinical trial: 1. aged 0-3 month infants; 2. Cholangiography confirmed biliary atresia; 3. Normal hematopoietic function; 4. Written informed consent from guardians.

Exclusion criteria

Exclusion criteria: ? Complications: Systemic inflammatory response syndrome or Multisystem malformation; ? Unclear diagnosis of primary disease; ? Unable to obtain parental authorization.

Design outcomes

Primary

Measure	Time frame
Liver function index;lymphocytes count;stool color;	—

Secondary

Measure	Time frame
Detection of autoantibody;Quantitative analysis of total Immunoglobulins;	—

Countries

China

Contacts

Public ContactZhe Wen

Guangzhou Women and Children Medical Center

wenzhe2005@163.com+86 18902268782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026